We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $200 · 21 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Does New Shelf Registration And Planned Insider Sale Shift The Bull Case For Insmed (INSM)? - simplywall.st
Does New Shelf Registration And Planned Insider Sale Shift The Bull Case For Insmed (INSM)? simplywall.st
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $237 - 富途牛牛
Barclays Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $237 富途牛牛
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference – Company Announcement - Financial Times
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference – Company Announcement Financial Times
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Rare Disease Growth Hopes - Sahm
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Rare Disease Growth Hopes Sahm
Insmed (INSM) slides 3% as investors weigh recent shelf registration and post-earnings reset - Quiver Quantitative
Insmed (INSM) slides 3% as investors weigh recent shelf registration and post-earnings reset Quiver Quantitative
Insmed Insider Sold Shares Worth $666,982, According to a Recent SEC Filing - Moomoo
Insmed Insider Sold Shares Worth $666,982, According to a Recent SEC Filing Moomoo
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.77 | — | — | $392.17M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-1.42 | — | — | $92.82M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-4.27 | — | — | $259.27M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-3.02 | — | — | $165.84M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 05. 09. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 08. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 08. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 04. 18. | Roth Capital | — | Maintain | Buy → Buy | — | Roth Capital: Buy |
| 2026. 04. 14. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 962,156 | $167.45B | 0.26% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 237,017 | $38.76B | 0.03% | — | New position |